Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Pfizer Inc
Femme et Homme Max 99 ans
Pfizer Inc.235 East 42nd Street, New York, NY 10017
MAJ Il y a 4 ans
A study to assess the efficacy, safety and tolerability of PF-04950615 following monthly and twice monthly injection dosing for six months in subjects on a statin with high cholesterol
To evaluate the LDL-C lowering effect of PF-04950615 administered subcutaneously at monthly intervals, or twice monthly intervals in hypercholesterolemic subjects whose LDL-cholesterol is ≥80 mg/dL on...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc.235 East 42nd Street, New York, NY 10017
MAJ Il y a 4 ans
A study to find out if a vaccine designed to protect against a disease (group B meningococcal meningitis) is safe and protects children aged from 24 months to less than 10 years
•To describe the immune response as measured by hSBA performed with 4 primary MnB test strains, 2 expressing an LP2086 subfamily A protein and 2 expressing an LP2086 subfamily B protein, measured 1 mo...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc
MAJ Il y a 4 ans
A six-month, open-label outpatient, parallel group trial assessing the impact of inhaled insulin (Exubera®) on glycemic control in patients with type 2 diabetes mellitus who are poorly controlled on two oral anti-diabetic agents
The primary objective is to compare the efficacy between subjects who are treated with the combination of OHA’s and Exubera® compared to subjects treated with usual diabetes care, by looking at the me...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc.235 East 42nd Street, New York, NY 10017
MAJ Il y a 4 ans
RANDOMIZED, DOUBLE-BLIND, 12-MONTH STUDY OF PREGABALIN IN SUBJECTS WITH RESTLESS LEGS SYNDROME
• To assess the efficacy of a fixed dose of pregabalin to placebo during the first 12 week treatment period in subjects with RLS. • To compare the rate of augmentation of a fixed dose of pregabalin t...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc.235 East 42nd Street, New York, NY 10017
MAJ Il y a 4 ans
A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED 26-WEEK TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF DIMEBON (LATREPIRDINE, PF-01913539) IN PATIENTS WITH MODERATE-TO-SEVERE ALZHEIMER’S DISEASE
The co-primary objectives of this study are: 1. To determine the effect of dimebon, as compared to placebo, on the primary measure of cognition, the Severe Impairment Battery (SIB) in patients with mo...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Pfizer Inc
MAJ Il y a 4 ans
A MULTIPLE DOSE, RANDOMIZED, DOUBLE-BLIND MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF PREGABALIN COMPARED TO PLACEBO IN THE TREATMENT OF PATIENTS WITH POST-SURGICAL PAIN FROM HYSTERECTOMY
The primary objective of this study is to assess the efficacy of pregabalin compared to placebo on pain following hysterectomy, measured using subject reported assessments of pain.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc 235 East 42nd Street, New York, NY10017
MAJ Il y a 4 ans
A study in patients with Non-Hodgkin Lymphoma (NHL) to evaluate safety and effectiveness of a new drug combination compared to 2 other drug combinations that have already been studied in clinical trials. This study will include patients who have already received therapy for their NHL (but it returned or was not completely cured), and now intense chemotherapy is not the best treatment option due to reasons like health or age. The types of NHL include Diffuse Large B-Cell Lymphoma and others
To evaluate efficacy as measured by overall survival (OS), with a goal of demonstrating the superiority of inotuzumab ozogamicin when administered in combination with rituximab, compared with an act...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Pfizer Inc
MAJ Il y a 4 ans
A PHASE 2 STUDY OF THE EFFICACY AND SAFETY OF SU-014813 IN PATIENTS WITH METASTATIC BREAST CANCER
To determine the antitumor efficacy of single agent SU-014813 at a dose of 100 mg orally once daily in patients with metastatic breast cancer
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc.235 East 42nd Street, New York, NY 10017
MAJ Il y a 4 ans
Study with investigational drug PF-06463922 in patients with a specific type of advanced lung cancer Estudio con fármaco en investigación PF-06463922 en pacientes con un tipo específico de cáncer de pulmón
This study has separate primary objectives for the two study portions: Phase 1 and Phase 2. Phase 1 study portion: To assess safety and tolerability of PF-06463922 as a single agent at increasing dose...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc
MAJ Il y a 4 ans
Randomized, Double-Blind, Placebo-Controlled Trial of etanercept plus methotrexate in monoclonal antibody (mAb) anti-TNF failure
To compare the efficacy of etanercept to placebo in inadequate responders to infliximab or adalimumab plus methotrexate (MTX) in all subjects and in subjects who are anti-drug antibody positive (ADA+)...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
6
7
8
9
10
11
12
13
14
15
Suivant